U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C26H35NO4.ClH
Molecular Weight 462.021
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DIPROTEVERINE HYDROCHLORIDE

SMILES

Cl.CCOC1=CC=C(CC2=NCCC3=CC(OC(C)C)=C(OC(C)C)C=C23)C=C1OCC

InChI

InChIKey=AWQPJKUSDUHYIX-UHFFFAOYSA-N
InChI=1S/C26H35NO4.ClH/c1-7-28-23-10-9-19(14-24(23)29-8-2)13-22-21-16-26(31-18(5)6)25(30-17(3)4)15-20(21)11-12-27-22;/h9-10,14-18H,7-8,11-13H2,1-6H3;1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C26H35NO4
Molecular Weight 425.5604
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Diproteverine is a calcium channel blocking agent. Diproteverine provoked a dose-dependent inhibition of LHRH-stimulated luteinizing hormone release. Diproteverine does not modify mean blood pressure. Diproteverine administered with and without pharmacologic autonomic blockade in the conscious dog causes dose-related depressant effects on sinus node function and atrioventricular conduction without producing significant vasodilatation. Diproteverine caused a redistribution of the available coronary blood flow, to the benefit of an ischemic area of the myocardium. The combination of the reduction in heart rate, to lower cardiac oxygen demand, with the beneficial action on coronary blood flow should result in diproteverinebeing particularly beneficial for the treatment of angina pectoris.

Approval Year

PubMed

PubMed

TitleDatePubMed
[Comparative effect of a new calcium antagonist, BRL 40015, and verapamil on LH secretion from cultured pituitary cells].
1985
Effects of diproteverine, a new calcium antagonist on sinoatrial node and atrioventricular conduction in conscious unsedated dogs.
1988 Oct
Ca2+ measurement with a Ca electrode: artifacts due to some cardiotropic drugs.
1988 Sep
Diproteverine (BRL 40015): a new type of calcium antagonist with potential antianginal properties.
1991 Jan 17
Prenatal toxicity studies in rats and rabbits with the calcium channel blocker diproteverine.
1996 Jan-Feb

Sample Use Guides

100 mg twice a day for 21 days
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:29:40 GMT 2023
Edited
by admin
on Fri Dec 15 15:29:40 GMT 2023
Record UNII
T587ZFV6UM
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DIPROTEVERINE HYDROCHLORIDE
Common Name English
ISOQUINOLINE, 1-((3,4-DIETHOXYPHENYL)METHYL)-3,4-DIHYDRO-6,7-BIS(1-METHYLETHOXY)-, HYDROCHLORIDE (1:1)
Systematic Name English
1-((3,4-DIETHOXYPHENYL)METHYL)-3,4-DIHYDRO-6,7-BIS(1-METHYLETHOXY)ISOQUINOLINE, HYDROCHLORIDE
Systematic Name English
BRL-40015A
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C333
Created by admin on Fri Dec 15 15:29:40 GMT 2023 , Edited by admin on Fri Dec 15 15:29:40 GMT 2023
Code System Code Type Description
MESH
C049847
Created by admin on Fri Dec 15 15:29:40 GMT 2023 , Edited by admin on Fri Dec 15 15:29:40 GMT 2023
PRIMARY
NCI_THESAURUS
C97979
Created by admin on Fri Dec 15 15:29:40 GMT 2023 , Edited by admin on Fri Dec 15 15:29:40 GMT 2023
PRIMARY
EPA CompTox
DTXSID30219461
Created by admin on Fri Dec 15 15:29:40 GMT 2023 , Edited by admin on Fri Dec 15 15:29:40 GMT 2023
PRIMARY
FDA UNII
T587ZFV6UM
Created by admin on Fri Dec 15 15:29:40 GMT 2023 , Edited by admin on Fri Dec 15 15:29:40 GMT 2023
PRIMARY
CAS
69373-88-2
Created by admin on Fri Dec 15 15:29:40 GMT 2023 , Edited by admin on Fri Dec 15 15:29:40 GMT 2023
PRIMARY
PUBCHEM
3052867
Created by admin on Fri Dec 15 15:29:40 GMT 2023 , Edited by admin on Fri Dec 15 15:29:40 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY